India’s Zydus Has Expansion Plans In Japan After Nippon Acquisition
This article was originally published in PharmAsia News
Executive Summary
Zydus Cadila, an Indian pharmaceutical company, plans to release its first new generic drug in 10 years and expand its portfolio of other generics in Japan. Zydus acquired the Japanese generics maker, Nippon Universal Pharmaceutical, last April. The new drug launched by Zydus is a generic of UCB Japan's Zyrtec (cetirizine hydrochloride) for treating allergies. The Nippon arm plans to acquire the sales rights for nine other generics drugs to add to its portfolio of six, and increase its sales representative staff from 11 to 25 by next October. (Click here for more - may require a subscription
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.